Media
[News] Hua Medicine will present multiple research results at the 2024 American Diabetes Association (ADA) Annual Scientific Sessions
June 17, 2024 - China, Shanghai
Hua Medicine (the "Company", HKEx stock code: 2552) announced today that its wholly owned subsidiary Nanjing AscendRare Pharmaceutical Technology Co., Ltd.(AscendRare) will present multiple research findings at the 84th American Diabetes Association (ADA) Annual Scientific Sessions.
Hua Medicine and AscendRare will present multiple latest research results through poster presentations. These latest research results show that Hua Medicine is continuously expanding the depth and breadth of its research on glucokinase, while also actively conducting research on new targets and drug mechanisms to explore more disease areas and new drug development pipelines.
The ADA Annual Scientific Sessions is the largest and most important diabetes conference in the world. Every year, tens of thousands of researchers and practitioners from all over the world attend this event to report and exchange significant progress in diabetes research and treatment. Since 2014, Hua Medicine and its clinical experts have consistently presented innovative and groundbreaking results of basic and clinical research in the field of metabolic disease at the ADA Annual Scientific Sessions.
This year's ADA Annual Scientific Sessions will be held in Orlando, USA from June 21st to 24th, 2024.
Hua Medicine Shcedule
Poster code: 879-P | |
Title: | The Effects of the Combination of Dorzagliatin and Canagliflozin on Glucose Homeostasis in Mice |
Partners: | Nanjing AscendRare Pharmaceutical Technology Co., Ltd. |
Main content: | This study has verified that GKA dorzagliatin and SGLT2i canagliflozin reduce glucose levels through distinct mechanisms. GKA achieves this by enhancing the secretion of insulin and GLP-1, while SGLT2i reduced glucose levels without affecting glycemic hormone secretion. Both mechanisms of action and beneficial effects on glucose homeostasis are preserved when two drugs are combined. |
Poster code: 1887-LB | |
Title: | Effect of dorzagliatin, a dual-acting glucokinase activator on insulin and glucagon secretion impaired and normal glucose tolerance |
Partners: |
Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong |
Main content: | By studying the effects of single dose (50 mg) dorzagliatin on insulin secretion and glucagon suppression during hyperglycemic clamp in patients with impaired glucose tolerance (IGT) and normal glucose tolerant （NGT）, the research found that dorzagliatin increased second-phase insulin secretion in patients with IGT and basal insulin secretion in NGT, while improved the glucose-suppressed glucagon secretion in NGT. |
Poster code: 1740-P | |
Title: | The Effects of SGLT2 Inhibitor Canagliflozin on Glucagon Secretion in SUR1 Knockout Mice |
Partners: | Peking University First Hospital |
Main content | This study showed that in normal condition, canagliflozin has no affection on glucagon secretion. However, when α-cells were depolarized by KATP channel deletion, canagliflozin stimulated glucagon secretion both in vivo and in isolated islets, suggesting that SGLT2 inhibitors have intrinsic effects on α-cells. |
Poster code: 1748-P | |
Title: | NMDA Receptor is Involved in Amplification Effects of Glycine on Insulin Secretion |
Partners: | Peking University First Hospital |
Main content: | The study has shown that glycine enhances GSIS through the involvement of the NMDA receptor pathway. In contrast to the central nervous system, the NMDA receptor in islets is no longer responsive to stimulation by glutamate. However, it still exhibits a robust response to glycine. While the NMDA receptor is present in islets, it may be regulated and sensed differently compared to the central nervous system. This research provided new direction for the research of islet-central nervous system. |
About Hua Medicine
Hua Medicine is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong, China. Hua Medicine is focused on developing novel therapies for patients around the world with unmet medical needs. Based on global resources, Hua Medicine teams up with high-caliber people to develop breakthrough technologies and products, which contribute to global innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (華堂寧?) (dorzagliatin tablets) targets the glucose sensor glucokinase, restores glucose sensitivity in Type 2 diabetes (T2D) patients and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30, 2022. It can be used alone or in combination with metformin in metformin hydrochloride-tolerated T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used by patients with T2D with varying degrees of renal function impairment (including end-stage renal impairment without dialysis). Hua Medicine has partnered with Bayer, a leading global pharmaceutical company, to commercialize HuaTangNing (華堂寧?) in China, benefiting diabetes patients and their families.
About AscendRare
Nanjing AscendRare Pharmaceutical Technology Co., Ltd is a wholly owned subsidiary of Hua Medicine, situated within the Nanjing Biotech and Pharmaceutical Valley in the Jiangbei New District. The company's primary focus lies in conducting research and development (R&D) activities pertaining to pharmaceuticals, specifically targeting the treatment of rare metabolic diseases. The overarching goal is to develop and deliver efficacious therapeutic interventions for rare metabolic diseases, with a particular emphasis on newborn hypoglycemia. Additionally, the company offers supplementary diagnostic services for rare diseases, encompassing functional investigations of mutant genes. The company has implemented an extensive pre-clinical research and development (R&D) technology platform. This platform encompasses various components such as computer-aided drug screening, compound optimization and synthesis, target protein function testing, compound screening, drug screening based on islet function, and drug efficacy determination using disease animal models. The company has also established R&D pipelines targeting different objectives. The company has been designated as a "Private Technology Enterprise," a "Small and Medium-sized Technology Enterprise," and an "Innovative Small and Medium-sized Enterprise." It has collaborated with numerous domestic and international universities and scientific research institutes to consistently broaden the investigation of illness mechanisms alongside the development of groundbreaking pharmaceuticals.
For more information
Hua Medicine
Website: yi92.cn
Investors
E-mail: ir@huamedicine.com
Media
E-mail: pr@huamedicine.com
滬ICP備14036654號-1
滬公網(wǎng)安備 31011502013809號 Privacy Statement Terms of Use
